Treatment options that have been tried include zidovudine and the CHOP regimen. Pralatrexate has also been investigated. Recently, it has been reported that the traditional glucocorticoid-based chemotherapy toward<unk>  are largely mediated by thioredoxin binding protein-2 (TBP-2/TXNIP/VDUP1), suggesting the potential use of a TBP-2 inducer as a novel therapeutic target. In 2021, mogamulizumab was approved for relapsed/refractor treatment of<unk>  in Japan. At a medical conference in December 2013, researchers reported anywhere from 21-50% of<unk>  patients have disease expressing CD30. Although not FDA approved, treatment with CD30-targeting brentuximab vedotin in CD 30+ cases may be beneficial and supported by current NCCN guidelines.
Adult T-cell leukemia/lymphoma
T-lymphoblastic leukemia/lymphoma
Thymoma with immunodeficiency
Atypical chronic myeloid leukemia
AIDS-related lymphoma
Aggressive NK-cell leukemia
T-cell acute lymphoblastic leukemia
B-cell prolymphocytic leukemia